Core Viewpoint - PAVmed has successfully closed financings that eliminate all previously outstanding convertible securities, significantly strengthening its balance sheet and capital structure [1] Financing Details - The Series D Preferred Stock offering generated $30 million in gross proceeds, with warrants for an additional $30 million contingent on a positive Medicare local coverage determination for the EsoGuard test [1] - A new senior secured note with a three-year maturity raised an additional $15 million [1] - The total net cash proceeds from these transactions amount to approximately $7.7 million, which will be used for general working capital [1] Capital Structure Improvement - The proceeds from the financings were utilized to redeem all outstanding Series C Convertible Preferred Stock and fully retire existing convertible debt [1] - Assuming the exercise of associated warrants and conversion of Series D Preferred Stock, the company could achieve a clean capital structure consisting entirely of common stock and long-term debt, adding approximately $37.7 million in cash to the balance sheet [1] Strategic Positioning - PAVmed's Chairman and CEO highlighted that this transaction is a transformative outcome aimed at fixing the legacy capital structure and unlocking the company's asset strength for shareholders [1] - The company is now positioned to pursue additional commercial opportunities and enhance long-term shareholder value, leveraging its subsidiaries, including Lucid Diagnostics and Veris Health [1]

Market Overview - U.S. stocks showed mixed performance with the Dow up 0.30% to 48,632.75, the S&P 500 rising 0.16% to 6,807.83, while the Nasdaq fell 0.06% to 22,940.77 [1] - European shares were also mixed, with the eurozone's STOXX 600 gaining 0.03% and Germany's DAX falling 0.47% [8] - Asian markets closed mixed, with Japan's Nikkei down 0.41% and Hong Kong's Hang Seng Index up 0.37% [11] Sector Performance - Energy shares increased by 2% on Wednesday, while consumer staples stocks dipped by 0.5% [2] Company Earnings - Johnson & Johnson reported fourth-quarter earnings of $2.46 per share, a 20.6% increase year-over-year, surpassing the consensus estimate of $2.44 [3] - The company also reported sales of $24.56 billion, up 9.1% year-over-year, exceeding the consensus of $24.16 billion [3] - For fiscal 2026, Johnson & Johnson provided adjusted earnings guidance of $11.43-$11.63, slightly above the consensus of $11.45, and expects sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion [4] Notable Stock Movements - PAVmed Inc shares surged 246% to $21.43 after a contract award for its EsoGuard Esophageal DNA Test [10] - Progress Software Corp shares rose 22% to $47.08 following better-than-expected fourth-quarter results and positive guidance [10] - Lisata Therapeutics Inc shares increased by 86% to $4.01 after announcing a binding term sheet for acquisition [10] - Venus Concept Inc shares dropped 55% to $1.99 due to plans to delist from Nasdaq [10] - Gibraltar Industries Inc shares fell 18% to $44.70 after reporting preliminary fourth-quarter results below estimates [10]

Market Overview - U.S. stocks showed mixed performance with the Dow up 0.30% to 48,632.75, the S&P 500 rising 0.16% to 6,807.83, while the Nasdaq fell 0.06% to 22,940.77 [1] Sector Performance - Energy shares increased by 2% on Wednesday, while consumer staples stocks decreased by 0.5% [2] Company Earnings - Johnson & Johnson reported fourth-quarter earnings of $2.46 per share, a 20.6% increase year over year, surpassing the consensus estimate of $2.44. The company also reported sales of $24.56 billion, up 9.1% year over year, exceeding the consensus of $24.16 billion [3] - For fiscal 2026, Johnson & Johnson provided adjusted earnings guidance of $11.43-$11.63, slightly above the consensus of $11.45, and expects sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion [4] Stock Movements - PAVmed Inc shares surged 246% to $21.43 after a contract award for its EsoGuard Esophageal DNA Test [10] - Progress Software Corp shares rose 22% to $47.08 following better-than-expected fourth-quarter results and positive first-quarter guidance [10] - Lisata Therapeutics Inc shares increased by 86% to $4.01 after announcing a binding term sheet for acquisition at $4.00 per share [10] - Venus Concept Inc shares fell 55% to $1.99 after announcing plans to delist from Nasdaq [10] - Innovation Beverage Group Ltd shares dropped 38% to $0.96 after a business update regarding energy expansion and a proposed merger [10] - Gibraltar Industries Inc shares declined 18% to $44.70 after reporting preliminary fourth-quarter results below estimates [10] International Markets - European shares were mixed, with the eurozone's STOXX 600 gaining 0.03%, while Spain's IBEX 35 rose 0.19%. London's FTSE 100 increased by 0.27%, Germany's DAX fell 0.47%, and France's CAC 40 gained 0.14% [8] - Asian markets closed mixed, with Japan's Nikkei down 0.41%, Hong Kong's Hang Seng Index up 0.37%, China's Shanghai Composite up 0.08%, and India's BSE Sensex down 0.33% [11]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 300 points, up 0.63% to 48,792.32, while the NASDAQ rose 0.75% to 23,126.84, and the S&P 500 gained 0.73% to 6,846.72 [1] Company Performance - Netflix, Inc. (NASDAQ:NFLX) shares declined around 3% after reporting fourth-quarter financial results and providing first-quarter guidance that fell below estimates. The company reported earnings per share of 56 cents, surpassing the consensus estimate of 55 cents, and revenue of $12.05 billion, exceeding the consensus estimate of $11.97 billion [2] - For the first quarter, Netflix guided for earnings per share of 76 cents and revenue of approximately $12.16 billion, indicating expectations for continued advertising revenue growth and plans to invest in content, advertising initiatives, and newer formats such as live events, video podcasts, and games [3] Commodity Market - In commodity news, oil prices increased by 0.1% to $60.40, while gold rose by 2.4% to $4,880.20. Silver traded up 0.2% to $94.825, and copper saw a rise of 0.7% to $5.8525 [6] European Market - European shares showed a decline, with the eurozone's STOXX 600 falling by 0.8%, Spain's IBEX 35 Index down 1%, London's FTSE 100 decreasing by 0.1%, Germany's DAX falling by 1.4%, and France's CAC 40 slipping by 0.5% [7] Asian Market - Asian markets closed mixed, with Japan's Nikkei down 0.41%, Hong Kong's Hang Seng Index up 0.37%, China's Shanghai Composite gaining 0.08%, and India's BSE Sensex falling by 0.33% [10] Notable Stock Movements - PAVmed Inc (NASDAQ:PAVM) shares surged 232% to $20.57 following a contract award to its subsidiary for the EsoGuard Esophageal DNA Test. Smart Logistics Global Ltd (NASDAQ:SLGB) shares increased by 141% to $2.97. Lisata Therapeutics Inc (NASDAQ:LSTA) shares rose by 85% to $4.00 after announcing a binding term sheet for acquisition at $4.00 per share [9] - Conversely, Venus Concept Inc (NASDAQ:VERO) shares dropped 52% to $2.16 due to an announcement of delisting from Nasdaq, while Innovation Beverage Group Ltd (NASDAQ:IBG) shares fell 39% to $0.95 following a business update [9]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 300 points, up 0.63% to 48,792.32, while the NASDAQ rose 0.75% to 23,126.84, and the S&P 500 gained 0.73% to 6,846.72 [1] Company Performance - Netflix, Inc. (NASDAQ:NFLX) shares declined around 3% after reporting fourth-quarter financial results and providing first-quarter guidance that fell below estimates. The company reported earnings per share of 56 cents, surpassing the consensus estimate of 55 cents, and revenue of $12.05 billion, exceeding the consensus estimate of $11.97 billion [2] - For the first quarter, Netflix guided for earnings per share of 76 cents and revenue of approximately $12.16 billion, indicating expectations for continued advertising revenue growth and plans to invest in content, advertising initiatives, and newer formats such as live events, video podcasts, and games [3] Commodity Market - In commodity news, oil prices increased by 0.1% to $60.40, while gold rose by 2.4% to $4,880.20. Silver traded up 0.2% to $94.825, and copper saw a rise of 0.7% to $5.8525 [6] European Market - European shares showed a decline, with the eurozone's STOXX 600 falling by 0.8%, Spain's IBEX 35 Index down 1%, London's FTSE 100 decreasing by 0.1%, Germany's DAX down 1.4%, and France's CAC 40 slipping by 0.5% [7] Asian Market - Asian markets closed mixed, with Japan's Nikkei falling by 0.41%, Hong Kong's Hang Seng Index gaining 0.37%, China's Shanghai Composite up by 0.08%, and India's BSE Sensex down by 0.33% [10] Notable Stock Movements - PAVmed Inc (NASDAQ:PAVM) shares surged by 232% to $20.57 following a contract award to its subsidiary for the EsoGuard Esophageal DNA Test. Smart Logistics Global Ltd (NASDAQ:SLGB) shares increased by 141% to $2.97, while Lisata Therapeutics Inc (NASDAQ:LSTA) shares rose by 85% to $4.00 after announcing a binding term sheet for acquisition at $4.00 per share [9]

Business Performance - Lucid Diagnostics achieved a record quarterly revenue of $1.2 million in Q3 2024, a 20% increase compared to the previous quarter[6] - EsoGuard test volume reached 2,787 in Q3 2024[6] - Over 7,000 firefighters have undergone EsoGuard esophageal precancer testing[6] - Year-to-date revenue for 3Q24 reached $3.149 million, a $1.761 million increase compared to $1.388 million in 3Q23[34] Strategic Accomplishments - The ESOGUARD BE-1 clinical validation study was accepted for peer-reviewed publication[8] - A key patent underlying EsoGuard received a Notice of Allowance[8] - Lucid Diagnostics met with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's Molecular Diagnostics Program (MolDX) to discuss EsoGuard clinical evidence package for upcoming submission for Medicare coverage[8] Financials - Cash reserves decreased from $24.920 million in 2Q24 to $14.489 million in 3Q24, a decrease of $10.431 million[32] - Net loss for 3Q24 was $(12.371) million, compared to $(14.208) million in 3Q23, an improvement of $1.837 million[34] - Non-GAAP adjusted loss per share improved from $(0.22) in 3Q23 to $(0.20) in 3Q24[34] - Shares outstanding increased from 49.3 million in 2Q24 to 51.6 million in 3Q24, an increase of 2.3 million shares[32]

Core Points - PAVmed Inc. will host a business update conference call and webcast on November 13, 2025, at 8:30 AM ET, where the CEO will discuss the company's operations and growth strategy, and the CFO will present the third quarter 2025 financial results [1][2]. Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics, focuses on cancer prevention with products like the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer [4]. - Another subsidiary, Veris Health Inc., is dedicated to personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices. Veris is also developing an implantable physiological monitor to work alongside chemotherapy ports [4].

Core Insights - PAVmed Inc. and its subsidiary Veris Health have entered the commercial phase of their partnership with The Ohio State University Comprehensive Cancer Center to enhance personalized cancer care through the Veris Cancer Care Platform [1][2] Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in medical devices, diagnostics, and digital health sectors [5] - Veris Health, a majority-owned subsidiary of PAVmed, focuses on digital health and has developed a digital cancer care platform aimed at improving personalized cancer care through remote patient monitoring [5] Partnership Details - The partnership with OSUCCC – James aims to expand the clinical deployment of the Veris platform, which includes launching a clinical registry for patients enrolled in the program [2] - The Veris Cancer Care Platform features remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration [2][3] Platform Features - Patients enrolled in the Veris platform receive a VerisBox™ containing connected health care devices that transmit physiological data to a cloud-based clinician portal [3] - A patient portal allows symptom reporting and health tracking via a smartphone app, which also enables family members to participate in the patient's care journey [3] Future Developments - Veris is developing an implantable physiological monitor to be used alongside a vascular access port, enhancing the platform's clinical and commercial value by providing remote data independent of patient compliance [3]

Core Insights - Lucid Diagnostics Inc. has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs to enhance market access infrastructure and accelerate commercial coverage expansion for its EsoGuard Esophageal DNA Test [1][2] - The company is at a critical juncture, aiming to expand patient access to the EsoGuard test, with Medicare coverage anticipated following a positive MolDX CAC meeting [2][3] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer [3] - The EsoGuard test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [3] Leadership and Experience - Danielle Scelfo brings over 25 years of experience in market access, reimbursement, and government affairs, having held senior roles in various diagnostics companies [2][3] - Her previous positions include Vice President at ClearNote Health and leadership roles at CareDx, Hologic, Adaptive Biotechnologies, and Genomic Health [2]